Trust LegalMatch to find you the RIGHT Lawyer!  

Home  Top Stories  Sports  Entertainment  Health News  Business  Personal Finance 
Real Estate  Business Finance  Insurance  Consulting 
Tax News  Forum


 

Writers






 


Featured Articles







BUSINESS



 


 

Find a Lawyer - LegalMatch

Create Your Own WILL @ Legalzoom

Legal Documents ONLINE @ Legalzoom

 

 



Merck May Have Concealed Heart Attack Events in Vioxx Study

December 8th 2005

Merck May Have Concealed Heart Attack Events in Vioxx Study

NEJM

The New England Journal of Medicine made a public allegation stating that two of the authors of the Canadian-led study withheld data concerning Vioxx.  The original study was first published in the New England Journal of Medicine back in November 2000. 

There were three heart attacks withheld by two researchers among the subjects taking the drug.  The heart attacks were not disclosed according to the journals editor-in-chief, executive editor and co-author.  This information was made public in a press release by the journal.  

There were other adverse cardiovascular events that were deleted from the original data / manuscript just two days before it was submitted for publication.  This has come to light after an analysis of a computer disk.

 

This could be damaging for Merck since there are numerous lawsuits involving the pain killer Vioxx.  The New York Times claims ” Merck misrepresented the results of a crucial clinical trial of Vioxx to play down the drug's heart risks”.  Two of the authors listed on the paper were employees of Merck.  Dr. Alise Reicin and Deborah Shapiro were both employees, and Dr. Reicin is Mercks’s vice president for clinical research.  The journal did not name these or any other researchers as the ones that modified the data.

It was reported by the Toronto Star that Merck has defended the research stating that the “three heart attacks had occurred after a pre-specified cut-off date”.  The journal (NEJM) press release also stated “Nevertheless, these additional events were disclosed to the FDA in 2000, presented publicly at the FDA's advisory committee in February 2001, and included in numerous press releases subsequently issued by Merck."

The Star also reported that Dr. Claire Bombardier, lead author of the original study funded by Merck and rheumatologist at the Toronto’s Mount Sinai Hospital said “I believe that the VIGOR paper appropriately disclosed the data as per the pre-specified plan of analysis."

 
Comment on this Article at our Forum

Submit your own Article

Special Topic: The Law

  RSS Feed to our business feed

  RSS Feed to all of our content

Add to My Yahoo!

Subscribe with Pluck RSS reader

 

By Dan Wilson
Best Syndication Staff Writer

Related Books

Keywords and misspellings: Viox vioxe vioxx Merk merck meark merc lawyer laywer layer


Google
 
Web BestSyndication.com

About   Contact   site map

Copyright 2005 Best Syndication                                            Last Updated Saturday, July 10, 2010 09:40 PM